Abstract
Do molecularly-targeted contrast agents have what it takes to usher in a paradigm shift as to how we will image cardiovascular disease in the near future? Moreover, are non-invasive vulnerable plaque detection and preemptive treatments with these novel nanoparticulate agents within reach for clinical applications? In this article, we attempt to make a compelling case for how the advent of molecularly-targeted nanoparticle technology may change the way we detect atherosclerotic lesions, determine their clinical significance and even provide non-invasive treatments. Focusing on imaging with cardiovascular MR, an overview of the latest developments in this rapidly evolving field of so-called "intelligent" contrast agents that are able to interrogate the vascular wall and various complementary advanced imaging technologies are presented.
Original language | English |
---|---|
Pages (from-to) | 827-843 |
Number of pages | 17 |
Journal | Journal of Cardiovascular Magnetic Resonance |
Volume | 9 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2007 |
Keywords
- Atherosclerosis
- Contrast Agent
- MRI
- Molecular Targeting
- Nanoparticle
- Vulnerable Plaque